American Journal of Transplantation

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Retrieved on: 
Monday, October 2, 2023
Duke University, Pediatrics, Duke University School of Medicine, Old Dominion University, National Institute of Diabetes and Digestive and Kidney Diseases, Research, Kidney, American Journal, Patient, Organ transplantation, Kidney transplantation, American Journal of Transplantation, Digestive, Plasma protein binding, Duke, Dentistry, Eledone

IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.
  • Dr. Kirk is internationally recognized for his work in organ transplantation, with a specialized focus on kidney transplants and transplant immunology.
  • Transplant recipients deserve new treatment options with better efficacy and fewer side-effects to help protect their transplanted organs,” said Dr. Kirk.
  • Dr. Kirk has helped pioneer the use of co-stimulation pathway blockade to prevent organ rejection in transplant patients.

Global Organ Preservation Market Report 2022: Rising Cases of Multiple Organ Failure in Ageing Population Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 26, 2022
Surgery, Health, Heart, Vein, COVID-19, Ageing, Legislation, Liver disease, Population, Tissue, Fatty liver disease, Pancreas, Government, Uniform, Uniform Anatomical Gift Act, American Journal of Transplantation, UAGA, NGO, Ligament, Liver, Family, Tendon, Skin, Death, Transplant, Organ transplantation, CAGR, Medical device, Dentistry, Growth

The "Organ Preservation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Organ Preservation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The organ preservation market studied is anticipated to grow with a CAGR of nearly 6.3%, during the forecast period.
  • Certain factors that are driving the market growth include rising cases of multiple organ failure in aging population, technological advancements, and increasing government and NGO initiatives to encourage organ donation.
  • All these factors create a favorable scenario for organ donation and organ transplant across the region, eventually fueling the market growth.

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook

Retrieved on: 
Thursday, February 10, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Omicron, Private Securities Litigation Reform Act, Viremia, Cytomegalovirus, JC, American Journal, BK, Technology transfer, BK virus, OMP, SOT, KT, American Journal of Transplantation, ODD, Degenerative disease, POC, European Medicines Agency, Twitter, Infection, VST, IND, HC, BKV, Respiratory syncytial virus, CMV, FDA, Risk, Patient, EBV, Safety, JCV, Liver, Adult, Review, Brain, Severe acute respiratory syndrome coronavirus 2, SEC, ADV, Organization, Human polyomavirus 2, Dialysis, Research, ASH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Hemorrhagic cystitis, HCT, Society, Food, LinkedIn, Immunodeficiency, COVID-19, Vaccine, Pharmaceutical industry, Medicine, Dentistry, Animal, Transplant

AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021.

Key Points: 
  • AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021.
  • The Phase 3 registrational study is expected to initiate in the first half of 2022.
  • In December 2021, AlloVir initiated a global Phase 3 registrational study of posoleucel for the treatment of AdV infections in adult and pediatric allo-HCT patients.
  • For fiscal year 2022, AlloVir expects operating expenses to be in the range of $130 million to $145 million, excluding non-cash stock compensation expenses.

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Retrieved on: 
Wednesday, January 12, 2022
Pancreatitis, Patient, Research, Annual report, Organ transplantation, Vaccine, Private Securities Litigation Reform Act, SEC, Form 10-K, COVID-19, Inflammation, Nasdaq, Safety, Program, Growth, NASDAQ, Transplant, American Journal of Transplantation, University, Disease, GLOBE, Department, American Journal, Bone marrow, Time, Infection, Immunosuppression, Marketing, Company, Mouse, TNFRSF25, Sale, Cancer, Immune system, Heat Biologics, FDA, Maintenance, Terminology, Pharmaceutical industry, Regulatory T cell, Heat

Disease protection in preclinical models was correlated with a significant expansion of Tregs and protection of the allograft, resulting in euglycemia and a graft survival benefit.

Key Points: 
  • Disease protection in preclinical models was correlated with a significant expansion of Tregs and protection of the allograft, resulting in euglycemia and a graft survival benefit.
  • Long-term surviving grafts showed a marked increase in Treg infiltration which directly correlated with mPTX-35 agonist activity.
  • Similar preclinical results have also been previously demonstrated for bone marrow, corneal and cardiac transplantation using these and other TNFRSF25 agonists.
  • Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system.

Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection

Retrieved on: 
Wednesday, October 27, 2021
Method, CMS, Accounting, Diagnosis, Technology, Cancer, Goal, Failure, Certification, LDT, IP, European Union, CLIA, Neoplasm, American Journal of Transplantation, Patient, Diversified Pharmaceutical Services, FDA, Food, Polymerase, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patent, Kidney, Forward-looking statement, Maintenance, Company, Clinical trial, CEO, COVID-19, Biomarker, Gold, LCD, Union, Cyprus Securities and Exchange Commission, Heart transplantation, Publication, Cell death, OCX, Intellectual property, Health, Tumor microenvironment, GLOBE, PLOS Medicine, Liver, Physician, DNA, Pharmaceutical industry, Medical imaging, Dentistry

IRVINE, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced the issuance of U.S. Patent No. 11,155,872 for digital polymerase chain reaction (dPCR) technique for molecular detection of solid organ allograft rejection. The new patent strengthens Oncocyte’s intellectual property portfolio in the blood-based monitoring market including the transplant setting, enabling Therasure Transplant Monitor, its donor-derived cell-free DNA (dd-cfDNA) test, access to the $2 billion U.S. transplant market. Therasure Transplant Monitor is a blood-based solid organ transplantation monitoring test that is designed to be used in lieu of a tissue biopsy in kidney, liver and heart transplant patients, minimizing the need for these invasive and costly procedures.

Key Points: 
  • 11,155,872 for digital polymerase chain reaction (dPCR) technique for molecular detection of solid organ allograft rejection.
  • The new patent strengthens Oncocytes intellectual property portfolio in the blood-based monitoring market including the transplant setting, enabling Therasure Transplant Monitor, its donor-derived cell-free DNA (dd-cfDNA) test, access to the $2 billion U.S. transplant market.
  • Oncocyte is currently validating the Therasure Transplant Monitor in its Nashville CLIA lab and is on track for a lab developed test (LDT) launch in the first half of 2022.
  • You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.